Today’s Stock Alerts include: Exxon Mobil Corp. (NYSE: XOM), International Business Machines Corp. (NYSE: IBM), Regeneron Pharmaceuticals Inc. (Nasdaq: REGN), Pfizer Inc. (NYSE: PFE), Wendy’s/Arby’s Group Inc. (NYSE: WEN), Human Genome Sciences Inc. (Nasdaq: HGSI).

Exxon Mobil Corp. (NYSE: XOM) Stock Alert - XOM, TransCanada Reach Agreement to Build a $26 billion Pipeline

Exxon Mobile Corp. (NYSE: XOM) shares slipped .86% to $73.39 in today’s early trading. The oil giant, which boasts of the largest proven natural gas reserves on the north slope of Alaska, recently reached an agreement to work together with TransCanada on a $26 billion Alaska Pipeline Project.

TransCanada’s Alaska Pipeline Project, poised to become one of world’s biggest engineering projects, is designed to deliver a reliable and secure source of clean energy to markets. The project secured a $500 million state subsidy after Alaska granted a state license for the pipeline following competitive bidding.

The project competes against one by rival Denali, owned by BP and ConocoPhillips, which Exxon Mobil reportedly declined to join last year.

In a joint statement, TransCanada and Exxon Mobil said they had “reached agreement on initial project terms,” without providing details. It also noted that TransCanada will remain the primary point of contact with the state of Alaska and the public.

TransCanada CEO Hal Kvisle said a timely completion of the project is expected with Exxon’s participation and the support of Alaska, the U.S. and the Canadian governments.

In a release, Rich Kruger, president of Exxon Mobil Production Company, made the following statement, “Exxon Mobil and TransCanada have the experience, expertise and financial capability to undertake this project. We have on-the-ground knowledge of Alaska and Canada, experience working in the Arctic, a strong history of technology and innovation, and the proven ability to build and operate projects of enormous scale in the most challenging environments.’’

According to state Revenue Commissioner Pat Galvin, Exxon, as partner with TransCanada, Exxon will be eligible for a state match of money spent to advance the project up to $500 million, under the terms of AGIA. In a report, he said the $150 million investment through the planned July 2010 open season will be shared by TransCanada and Exxon, and both companies will share in the state reimbursement.

Exxon Mobil through its divisions and affiliates is engaged in exploration for, and production of, crude oil and natural gas, manufacture of petroleum products and transportation and sale of crude oil, natural gas and petroleum products. It is a manufacturer and marketer of commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics and a wide variety of specialty products.

Exxon Mobil also has interests in electric power generation facilities. Affiliates of Exxon Mobil conduct research programs in support of these businesses. The company has several divisions and affiliates, many with names that include Exxon Mobil, Exxon, Esso or Mobil. The company operates in three segments: Upstream, Downstream and Chemicals.

In its recent chart, XOM’s MACD reflects a strong bullish signal, with the indicator above the 9-day moving average signal line, and also above the 0 level, indicating that moving averages are trending higher. With share prices currently above the stock’s 13-day moving average, a bullish trend is indicated. Also, a rising moving average signals that there has been buying interest in this stock. Trading within its Bollinger Bands, the stock reflects neither an overbought nor oversold condition relative to its recent price trend.

International Business Machines Corp. (NYSE: IBM) Stock Alert - IBM Partners with Curam Software to Improve Delivery of Social Services By Agencies

International Business Machines Corp. (NYSE: IBM) shares slipped .51% to $108.84 this morning. The Armonk, N.Y.-based information technology (IT) company, together with Curam Software, recently announced the integration of the Curam Business Application Suite with the IBM Business Process Management (BPM) software portfolio, a solution focused on improving information sharing through business process management.

IBM’s BPM solution is combined with the Curam Software solution, which is part of a new category of enterprise software called Social Enterprise Management (SEM) targeted at automating the operations of health, human services, workforce services, and social security agencies.

The companies said the joint solution will help social services agencies share information, reduce duplication and improve delivery of services to individuals and families.

In a release, Sandy Carter, vice president for IBM Software Group Channels, said, “The integration of Curam Software with the IBM BPM portfolio combines the advantages of commercial off-the-shelf software, an enterprise platform and service-oriented architecture with the business process management tools required by agencies to implement the solutions that meet their strategic objectives.”

Carter added this combination of industry leading platforms will help their joint clients to work more intelligently while eliminating redundancies and improving performance.

IBM’s major operations include Global Technology Services segment (GTS), Global Business Services segment (GBS), Software segment, Systems and Technology segment, and Global Financing segment. On January 31, 2008, the Company acquired 100% of Cognos Inc. On April 3, 2008, IBM acquired 100% of Telelogic, AB. In July 2008, the Company acquired Platform Solutions, Inc. (PSI). In December 2008, its internal global logistics operations were acquired by SNCF Transport and logistics division of Geodis.

In its recent chart, IBM is trading within its Bollinger Bands, a normal condition signaling that the stock is neither overbought nor oversold relative to the recent price action. MACD reflects a strong bullish signal, with the indicator above the 9-day moving average signal line, and also above the 0 level, indicating that moving averages are trending higher. With share prices currently above the stock’s 13-day moving average, a bullish trend is indicated. Also, a rising moving average signals that there has been buying interest in this stock.

Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) Stock Alert - REGN Provides Update on Ovarian Cancer Drug Collaboration with Sanofi

Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) shares slipped .81% this morning, trading at $15.94. Tarrytown, N.Y.-headquartered Regeneron Pharmaceuticals and Sanofi-Aventis recently said they will not submit data from the mid-stage study of their experimental drug, aflibercept, to treat ovarian cancer, despite meeting study goals of removing abdominal cavity fluid from advanced ovarian cancer patients. Both companies are collaborating on this drug to treat malignant ascites in ovarian cancer patients.

Regeneron cited difficulty in assessing the overall clinical benefit from the treatment.

In a release, George D. Yancopoulos, president of Regeneron Research laboratories, made the following statement, “Given the small number of patients enrolled in this study and the fragile health status of these advanced ovarian cancer patients, who had a median survival of only about three to four months, it is difficult to definitively assess the overall clinical benefit that might be derived from treatment in the real-world clinical practice setting.”

The company said it would instead focus its efforts on completing the current late-stage program, which combines aflibercept with standard chemotherapy regimens for the treatment of earlier stage metastatic colorectal, non-small cell lung, pancreatic, and prostate cancers.

Regeneron discovers, develops and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2008, the company had one marketed product: ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available for prescription in the United States for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS) and muckle-wells syndrome (MWS) in adults and children aged 12 and older.

Regeneron also has six clinical development programs, including three late-stage clinical programs. Aside from aflibercept (VEGF Trap), the company is developing VEGF Trap-Eye for eye diseases using intraocular delivery, which is in collaboration with Bayer HealthCare LLC, and ARCALYST for the treatment of gout.

In its recent chart, REGN’s MACD reflects a strong bullish signal, with the indicator above the 9-day moving average signal line, and also above the 0 level, indicating that moving averages are trending higher. With share prices currently above the stock’s 13-day moving average, a bullish trend is indicated. Also, a rising moving average signals that there has been buying interest in this stock. Trading within its Bollinger Bands, the stock reflects neither an overbought nor oversold condition relative to its recent price trend.

Pfizer Inc. (NYSE: PFE) Stock Alert - PFE Oral Rheumatoid Arthritis Drug Candidate Meets Key Goals; to Review Phase 2 Data

Pfizer Inc. (NYSE: PFE) shares climbed 1.44% to $14.86 this morning. The research-based, global pharmaceutical company, presenting at a medical meeting in Denmark this week, said its CP-690,550, an experimental oral treatment for rheumatoid arthritis has met key goals in two midstage studies by improving tender and swollen joints.

CP-690,550 is an oral, selective, potent inhibitor of the JAK family of enzymes that are involved in numerous inflammatory and autoimmune diseases, including RA. By inhibiting these enzymes, which affect the signaling of multiple cytokines (proteins released by cells to communicate with other cells) that are involved in a broad spectrum of inflammatory and autoimmune diseases, treatment with CP-690,550 may lead to clinically meaningful improvement for patients.

According to the data presented at the meeting, results showed that three-quarters of patients had at least a 20% improvement in their condition after 12 weeks of treatment with the new drug. A quarter of them experienced a 70% improvement.

“This compound could represent a promising advance in rheumatoid arthritis treatment for patients who need an alternative to currently available therapies,” said Michael Berelowitz, MD, senior vice president of Clinical Development and Medical Affairs for Pfizer Specialty Care.

Dr. Berelowitz continued, “The size of our comprehensive phase 2 program enabled us to identify doses for advancement into late-stage clinical trials.”

Pfizer announced it will Web cast a conference call with investment analysts at 1 p.m. ET on Friday, June 12, 2009, to review phase 2 data for CP-690,550.

Interested parties my visit www.pfizer.com and click on the “Pfizer Conference Call with Analysts at EULAR” link in the Investor Presentations tab to view and listen to the Web cast. Participants are advised to pre-register in advance of the conference call.

Pfizer discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals.

In June 2008, Pfizer completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc. through a merger of Pfizer’s wholly owned subsidiary, Explorer Acquisition Corp., with and into Encysive. In June 2008, it also completed the acquisition of Serenex Inc., a biotechnology company with a Heat Shock Protein 90 development portfolio. In January 2008, the company completed the acquisition of Coley Pharmaceutical Group Inc., a company whose area of capability is immunotherapy with emphasis on Toll-like receptor research and development.

In its recent chart, PFE is trading within its Bollinger Bands, a normal condition signaling that the stock is neither overbought nor oversold relative to the recent price action. MACD currently reflects weak bearish signal, with the indicator above the critical level of 0 but has crossed below its 9-day signal line, indicating that positive momentum. With share prices currently above the stock’s 13-day moving average, an indication of a bullish trend is generally considered.

Wendy’s/Arby’s Group Inc. (NYSE: WEN) Stock Alert - WEN Shares Decline on Word that it will sell $550 million in Senior Unsecured Notes

Wendy’s/Arby’s Group Inc. (NYSE: WEN) shares climbed 1.26% to $4.02 this morning. Shares of the Atlanta-based fast food chain were seen in the red Thursday after the company said it will sell $500 million in senior unsecured notes due in 2016.

In a release, the company said it intends to use the proceeds to optionally prepay approximately $125 million in borrowings outstanding under its existing senior secured term loan (and to pay accrued interest with respect to such borrowings), to pay the financing costs and other expenses in connection with the issuance of the Notes and to make a distribution of the remaining proceeds to Wendy’s/Arby’s Group.

Also, it said some of the money will go to Wendy’s/Arby’s Group for general corporate purposes, including funding growth initiatives and returning capital to shareholders in the form of stock buybacks or dividends.

CL King & Associates analyst Michael W. Gallo, who has a “Strong Buy” rating on the stock with a $7 price target, believes the company’s management is attempting to “opportunistically take advantage of a favorable interest rate environment.”

Wendy’s/Arby’s Group Inc., formerly Triarc Companies Inc., is the parent company of Wendy’s International Inc. (Wendy’s) and Arby’s Restaurant Group Inc. (ARG), which are the franchisors of the Wendy’s and Arby’s restaurant systems.

As of December 28, 2008, the Wendy’s restaurant system consisted of 6,630 restaurants, of which 1,406 were owned and operated by the company. As of December 28, 2008, the Arby’s restaurant system included 3,756 restaurants, of which 1,176 were owned and operated by the company. The company operates in two business segments: Wendy’s and Arby’s. On September 29, 2008, the company and Wendy’s completed the merger (the Wendy’s Merger).

In its recent chart, WEN’s MACD reflects a weak bullish signal, with the indicator trending above the 9-day moving average signal line but still below the 0 level, indicating bearish moving averages. With share prices currently below the stock’s 13-day moving average, the bearish sign is more pronounced with decreasing moving averages. Trading within its Bollinger Bands, the stock reflects neither an overbought nor oversold condition relative to its recent price trend.

Human Genome Sciences Inc. (Nasdaq: HGSI) Stock Alert - HGSI Shares Up on Lupus Drug Study Data

Human Genome Sciences Inc. (Nasdaq: HGSI) shares dropped 9.09% to $2.90 this morning. Shares of the commercially focused biopharmaceutical company were recently boosted on word its lupus drug, BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)), continued to show positive results in a mid-stage trial conducted over a period of four years.

In a press release, the company announced a continued treatment with belimumab showed sustained improvement or stabilization of the disease, systemic lupus erythematosus (SLE), or lupus, and decreased frequency of SLE disease flares in patients.

“We are encouraged by the sustained improvement in serologically active SLE patients treated with belimumab through four years,” said William W. Freimuth, M.D., Ph.D., vice president, Clinical Research - Immunology, Rheumatology and Infectious Diseases.

Dr. Freimuth continued, “We are also encouraged by the safety data presented at EULAR. The incidence rates per 100 patient years of all adverse event categories, including serious adverse events, overall adverse events, and serious infections were similar for belimumab and placebo during the 52-week double-blind period, and remained the same or decreased over four years of continuous treatment. Belimumab could represent a significant advance in the treatment of SLE if phase 2 results are confirmed in the phase 3 trials that are currently ongoing.”

Commenting on this development, Leerink Swann analyst Joseph Schwartz said the data makes him more positive on the expected results from the pivotal late-stage trial.

However, despite sustained improvement and no increase in serious adverse events in the mid-stage study, JMP Securities analyst Liisa Bayko maintained a cautious tone. Bayko stated, “I think the (phase 2 data) is still provocative. But we have to caution against how we think about this underscoring any confidence in the phase 3, which is at different time points.

Aside from Belimumab, HGS has two other products in late-stage clinical development: Albuferon for chronic hepatitis C, and ABthraxtm for inhalation anthrax.

December 2008, the company reported that Albuferon met its primary endpoint in the first of two phase 3 clinical trials in chronic hepatitis C. HGS also has several drugs in earlier stages of clinical development for the treatment of cancer, led by its TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins.

In its recent chart, HGSI is trading within its Bollinger Bands, a normal condition signaling that the stock is neither overbought nor oversold relative to the recent price action. MACD reflects a strong bullish signal, with the indicator above the 9-day moving average signal line, and also above the 0 level, indicating that moving averages are trending higher. With share prices currently above the stock’s 13-day moving average, a bullish trend is indicated. Also, a rising moving average signals that there has been buying interest in this stock.

InvestorSoup.com Research Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEB SITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and Web site have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. BlueWave Advisors LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the Web sites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.